Skip to main content

Table 4 Biodistribution results of [68Ga[Ga-DOTA-ST8950 at 1 and 2 h p.i. and [68Ga]Ga-DOTA-NOC at 1 h p.i

From: A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

[68Ga]Ga-DOTA-ST8950

[68Ga]Ga-DOTA-NOC

Organ

1 h#

2 h&

1 h (negative)‡

1 h&

Blood

1.9 ± 0.6

0.8 ± 0.2

1.5 ± 0.2

1.1 ± 0.4

Heart

1.3 ± 0.4

0.8 ± 0.2

1.1 ± 0.2

0.7 ± 0.2

Lung

5.4 ± 1.6

3.5 ± 0.7

4.6 ± 0.8

3.3 ± 1.4

Liver

6.4 ± 1.9

7.3 ± 1.5

6.2 ± 0.6

2.3 ± 0.7

Pancreas

8.5 ± 4.5

8.6 ± 2.1

7.4 ± 1.9

16 ± 3

Spleen

1.9 ± 0.6

1.5 ± 0.3

1.6 ± 0.1

0.8 ± 0.2

Stomach

7.5 ± 3.0

8.4 ± 1.2

6.0 ± 1.6

12 ± 2

Intestine

2.4 ± 1.3

2.7 ± 0.3

2.5 ± 0.2

3.3 ± 0.7

Adrenal

4.5 ± 0.9

4.3 ± 1.0

3.4 ± 0.7

4.6 ± 1.0

Kidney

14 ± 4

14 ± 2

12 ± 1

9.8 ± 3.2

Muscle

0.9 ± 0.3

0.6 ± 0.1

0.5 ± 0.1

0.5 ± 0.2

Femur

2.0 ± 0.6

2.4 ± 0.8

1.1 ± 0.1

1.7 ± 0.8

Pituitary

8.5 ± 1.9

7.8 ± 1.2

n.d.

8.2 ± 2.8

SST2 tumor

26 ± 8

32 ± 7

–

30 ± 8

SST5 tumor

15 ± 6

14 ± 3

–

12 ± 5

SST(-) tumor

–

–

1.4 ± 0.5

–

  1. Results are expressed as the mean of the % injected activity per gram of tissue (%IA/g) ± standard deviation (SD). The peptide mass and activity injected were 100 pmol and 2.5 MBq, for both radio-conjugates
  2. SST(-) somatostatin receptor negative
  3. #n = 8, &n = 5, ‡n = 3, n.d. not determined